459 results on '"Rausch, Steffen"'
Search Results
2. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma
3. Gegen Nectin-4 gerichtete Antikörper-Wirkstoff-Konjugate als neue Behandlungsoption für Patienten mit metastasiertem Urothelkarzinom
4. Real world data on IO-based therapy for metastatic renal cell carcinoma
5. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
6. Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions
7. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS)
8. Mikro-TESE versus Standard-TESE: für welchen Patienten welches OP-Verfahren?
9. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
10. ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).
11. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
12. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
13. Multiparametrische MRT der Prostata
14. Adressen
15. Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer
16. The regulation of FGF23 under physiological and pathophysiological conditions
17. Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
18. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
19. The role of planetary health in urologic oncology.
20. Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
21. PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy
22. Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer—An Exploratory Analysis of Clinical and Tumor Biological Significance
23. Bilirubin Down-Regulates Oxidative Stress and Fibroblast Growth Factor 23 Expression in UMR106 Osteoblast-Like Cells
24. Urothelial Cancer of the Upper Urinary Tract
25. The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
26. Minimal-invasive management of urological complications after kidney transplantation
27. Vitamin A regulates fibroblast growth factor 23 (FGF23)
28. Auswahlverfahren wissenschaftlicher Beiträge zum DGU-Kongress 2021
29. Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons
30. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin
31. Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.
32. Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions
33. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
34. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation
35. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
36. Prospective Analysis of Versatility and User Satisfaction with a Novel Single-Use Cystoscope with Working Channel
37. Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
38. Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
39. Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
40. MP14-19 ALTERATIONS OF INSULIN SIGNALING AND TUMOR BIOLOGY IN UROTHELIAL CARCINOMA OF DIABETIC AND NON-DIABETIC PATIENTS
41. PD36-01 NECTIN-4 PROTEIN EXPRESSION IN MUSCLE INVASIVE BLADDER CANCER - SELECTIVE PREDICTOR OR CONSISTENTLY EXPRESSED IN TUMOR TISSUE?
42. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
43. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
44. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
45. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS)
46. Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization
47. Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis
48. Impaired estimated glomerular filtration rate is a significant predictor for non–muscle-invasive bladder cancer recurrence and progression—Introducing a novel prognostic model for bladder cancer recurrence
49. Combination of PI-RADS score and mRNA urine test—A novel scoring system for improved detection of prostate cancer
50. Real world data on IO-based therapy for metastatic renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.